← Back to Search

Vaccine

HPV Vaccine Reminder Intervention for Healthy Young Men

N/A

Waitlist Available

Led By Paul Reiter, PhD

Research Sponsored by Ohio State University Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Cisgender male

Ages 18-25

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline up to 9 months

Awards & highlights

Study Summary

This trial will study how well a population-targeted, individually-tailored mHealth intervention that includes vaccine reminders works in increasing HPV vaccine initiation and completion among unvaccinated young sexual minority individuals.

Who is the study for?

This trial is for young cisgender males aged 18-25 in the US who identify as gay, bisexual, or queer, have not had any HPV vaccine doses, and can give informed consent. Participants must be able to read English and should not have taken part in the pilot study.Check my eligibility

What is being tested?

The trial tests the 'Outsmart HPV' intervention designed to increase HPV vaccine uptake among sexual minority males. It includes personalized mobile health components like reminders to initiate and complete the vaccination process.See study design

What are the potential side effects?

Since this trial focuses on an informational intervention rather than a medical treatment, traditional side effects are not applicable. However, participants may experience inconvenience or privacy concerns related to receiving text messages.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am a cisgender male.

Select...

I am between 18 and 25 years old.

Select...

I have never received an HPV vaccine.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline up to 9 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline up to 9 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to 9 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Changes in Theoretical Constructs

Counts of Human Papillomavirus (HPV) Vaccine Initiation by Participant Characteristics

Human Papillomavirus (HPV) Vaccine Initiation and Completion

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Group C (Outsmart HPV, interactive vaccine reminders)Experimental Treatment3 Interventions

Participants receive Outsmart HPV with interactive vaccine reminders (i.e. reminders that allow participants to respond).

Group II: Group B (Outsmart HPV, unidirectional vaccine reminders)Experimental Treatment3 Interventions

Participants receive Outsmart HPV with unidirectional vaccine reminders (i.e. reminders that do not give participants the option to respond).

Group III: Group A (standard HPV information)Active Control2 Interventions

Participants receive standard information about HPV and HPV vaccine via a mobile-friendly website.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor

320 Previous Clinical Trials

288,940 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,660 Previous Clinical Trials

40,923,294 Total Patients Enrolled

Paul Reiter, PhDPrincipal Investigator - Ohio State University Comprehensive Cancer Center

Ohio State University Comprehensive Cancer Center

2 Previous Clinical Trials

253 Total Patients Enrolled

Media Library

Outsmart HPV intervention (Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT04032106 — N/A

Healthy Subjects Research Study Groups: Group C (Outsmart HPV, interactive vaccine reminders), Group A (standard HPV information), Group B (Outsmart HPV, unidirectional vaccine reminders)

Healthy Subjects Clinical Trial 2023: Outsmart HPV intervention Highlights & Side Effects. Trial Name: NCT04032106 — N/A

Outsmart HPV intervention (Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04032106 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does my eligibility meet the criteria for inclusion in this investigation?

"This clinical trial seeks 158 volunteers aged 18 to 25 who identify as cisgender male, sexual minority (having had intimate interactions with males or being attracted to them; or identifying as gay, bisexual, queer), residing in the USA and have not previously been vaccinated for HPV. Additionally, these candidates must be literate in English and capable of providing informed approval by completing a screener survey and consent form."

Answered by AI

Is the age range for recruitment on this study inclusive of those over 20 years old?

"This clinical trial is strictly for people between 18 and 25 years old. Conversely, there are 50 studies that cater to minors and 371 trials dedicated towards senior citizens."

Answered by AI

Is this research protocol still recruiting participants?

"According to the information housed on clinicaltrials.gov, this research has achieved its patient quota and is no longer recruiting; however, 839 other studies are still searching for volunteers at current. This trial was initially posted in October of 2019 with a final update occurring in September 2022."

Answered by AI